With prospects for an AstraZeneca Plc deal falling apart, Pfizer Inc. Chief Executive Officer Ian Read is facing a new question from investors: What now?
Jeff Jonas, an analyst at Gabelli & Co., says he recommends shares of Bristol-Myers Squibb and Watson Pharmaceuticals. Jonas talks with Bloomberg's Ken Prewitt, Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."
Mylan Inc., the biggest U.S. generic-drug maker, was rejected in its bid to buy Meda AB, the Swedish pharmaceuticals maker valued at about $4.5 billion.
Covidien Plc., a maker of surgical products and drugs, plans to spin off its pharmaceuticals division into a separate company that would be better able to compete in the growing pain-management area.
"Jana Partners getting board seats is a very positive step and shows they are being pretty shareholder-friendly."
- Jeff Jonas on Sep 18, 2014
Bloomberg Surveillance: Levkovich, Moffatt and Jonas
Gabelli’s Jonas Says Pfizer Deal Will Get Done (Audio)
Gabelli’s Jonas Says CVS Can Maintain Current Growth (Audio)
Jonas Discusses Cigna Pharmacy-Benefits Division
Gabelli's Jonas, Edward Jones's Clark on CVS Outlook (Audio)